MiguelA.VillalonaMDFACP, FAAAS

Oncology • Orange, CA

Thoracic Cancer

Director Early Phase Therapeutics

Join to view full profile

Dr. Villalona is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Villalona's full profile

Already have an account?

Office
101 The City Dr S
Orange, CA 92868
Phone+1 714-456-8102

Education & Training

University of Texas Health Science Center San Antonio Joe and Teresa Lozano Long School of MedicineFellowship, Hematology and Medical Oncology, 1994 - 1995
University at BuffaloFellowship, Hematology and Medical Oncology, 1990 - 1992
University of MinnesotaFellowship, Hematology and Medical Oncology, 1989 - 1990
SUNY Downstate Health Sciences UniversityResidency, Internal Medicine, 1986 - 1989
Universidad Nacional Pedro Henriquez UrenaClass of 1985

Certifications & Licensure

CA State Medical License 2020 - 2026
FL State Medical License 1998 - 2025
KY State Medical License 2020 - 2021
OH State Medical License 1999 - 2017
TX State Medical License 1995 - 2010
AL State Medical License 1992 - 1996
MN State Medical License 1989 - 1994
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Fellow American Association for the Advancement of Science
Fellow American College of Physicians
Premio Fray Anton de Montesinos Asociacion de egresados UASD NYC
CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Join now to see all

Clinical Trials

Sequentially Administered CPT-11 and Mitomycin C in Patients With Advanced Esophageal and Stomach Cancer Start of enrollment: 2001 Sep 01
Completed
Phase 2
Phase I & Biological Study of Etanercept & Weekly Docetaxel in Patients With Advanced Solid Tumors Start of enrollment: 2000 Nov 01
Completed
Phase 1
Etanercept and Gemcitabine in Patients With Advanced, Chemotherapy Naive Pancreatic Adenocarcinoma Start of enrollment: 2001 Jul 01
Completed
Phase 1, Phase 2
OSI-774 in African American Patients With Advanced and Previously Treated Non-Small Cell Lung Cancer Start of enrollment: 2005 Oct 01
Completed
Phase 2
Sorafenib in Treating Non-Smokers or Former Light Smokers With Relapsed or Refractory Stage IIIB or Stage IV Non-Small Cell Lung Cancer Start of enrollment: 2008 Oct 01
Terminated
Phase 2
Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin for Non-Small Cell Lung Cancer With KRAS or EGFR Activation Start of enrollment: 2009 Mar 01
Completed
Phase 2
Veliparib With or Without Mitomycin C in Treating Patients With Metastatic, Unresectable, or Recurrent Solid Tumors Start of enrollment: 2009 Oct 01
Completed
Phase 1
Pembrolizumab Activity in Patients With Homologous Recombination Competent and Deficient Tumors Start of enrollment: 2017 Nov 03
Completed
Phase 2
Join now to see all

Publications & Presentations

PubMed

Phase II study of MEK inhibitor trametinib alone and in combination with AKT inhibitor GSK2141795/uprosertib in patients with metastatic triple negative breast cancer.
Vishnu Prasath, Hinda Boutrid, Robert Wesolowski, Mahmoud Abdel-Rasoul, Cynthia Timmers
Breast Cancer Research and Treatment. 2024-12-07
Atezolizumab combined with immunogenic salvage chemoimmunotherapy in patients with transformed diffuse large B-cell lymphoma.
Tamer Othman, Paul Frankel, Pamela Allen, Leslie L Popplewell, Geoffrey Shouse
Haematologica. 2024-07-18
Preclinical Evaluation of Off-The-Shelf PD-L1+ Human Natural Killer Cells Secreting IL15 to Treat Non-Small Cell Lung Cancer.
Ting Lu, Rui Ma, Anthony G Mansour, Christian Bustillos, Zhiyao Li
Cancer Immunology Research. 2024-06-04

Press Mentions

New Advances in Treating Lung Cancer, the Deadliest CancerMay 20th, 2016

Grant Support

Targeting Somatic Homologous Recombination In Solid TumorsNational Cancer Institute2010–2012
Early Therapeutics Development With Phase II EmphasisNational Cancer Institute2011
Early Therapeutics Development With Phase II EmphasisNational Cancer Institute2010
Tas:: 75 0850 ::Tas Recovery ACT - Actnow Clinical Trial 8472Division Of Cancer Treatment2009
Early Therapeutics Development With Phase II EmphasisDivision Of Cancer Treatment2009
Biomodulation Of Capecitabine By Docetaxel In Non-Small*National Cancer Institute2004–2005
TNF Blockade In Pancreatic Cancer PatientsNational Cancer Institute2003–2004
Phase II Randomized Trial Of CPT-11 And Mitomycin CNational Cancer Institute2002–2003
Phase I Study Of Sequential CPT 11 &Mitomycin CNational Center For Research Resources1999–2002
Translational Research In Lung CancerNational Cancer Institute1998–2002
Phase I Study To Determine The Safety Of Ecteinascidin-743National Center For Research Resources1997–2000
Phase I Protocol To Determine The Safety Of Lu79553 As An IV Infusion Daily X 5National Center For Research Resources1998–1999
Phase I Trial Of PN401 As Rescue Agent For Escalating Doses Of 5-FUNational Center For Research Resources1997–1999
Translational Research In Lung CancerNational Cancer Institute1997–1998
Phase I Protocolto Determine The Safety Of Lu79553 As An IV Infusion Daily X 5National Center For Research Resources1997
Effect Of H Corticotropin Releasing Factor On Peritumoral BrainNational Center For Research Resources1996